Case Challenge

Treatment of a 32-Year-Old Patient With HER2-Positive Breast Cancer

Source: Adjuvant HER2-Positive Cancer: Integrating Prognostic Tools and Clinical Advances to Optimize Treatment

Treatment of a 32-Year-Old Patient With HER2-Positive Breast Cancer


Faculty:

  • Daniel F. Hayes, MD
  • Jeffrey B. Smerage, MD, PhD

CME CREDIT INFORMATION

Release Date: 11/15/07

Expiration Date: 11/14/08


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify appropriate adjuvant therapy for hormone receptor–negative, HER2-positive breast cancer
  • Review current guidelines for the management of cardiotoxicity due to HER2-targeted breast cancer therapy
  • Describe the options available for the treatment of metastatic HER2-positive breast cancer

Test your ability to make optimal treatment decisions using patient histories and diagnostic information and see the case unfold according to your choices. Compare your answers with your peers and our expert faculty’s recommendations, and then review the supporting data.
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grant provided by:

Educational grants support only the CME-certified components of this program.